Christy Zito — Senator Burt questioned whether the proposed labeling requirements would conflict with FDA-regulated labeling and asked if there had been any communication with the federal government. He then asked whether there was any written federal guidance supporting the practicality of the approach in Idaho, and followed up by asking for examples of prior state legislation that had allowed additional information on labels beyond federal regulatory requirements.
Christy Zito — Voted nay on the substitute motion to hold Senate Bill 1310 in committee.
Todd Lakey — Identified as the second on the motion to adopt the minutes.
Todd Lakey — Thanked Mr. Seelick for his service and began asking about the future of the retirement system.
Todd Lakey — Praised PERSI and asked the nominee about future priorities.
Todd Lakey — Seconded the motion on House Bill 543.
Todd Lakey — The chair asks for closing remarks from Representative Ehlers and/or Senator Nichols; no member-specific speaker is clearly identified here beyond the ongoing bill discussion.
Todd Lakey — Makes a motion to send House Bill 563 to the floor with a due pass recommendation.
Todd Lakey — Jarnigan said she worked with him to bring the bill forward.
Christy Zito — Senator Christy Zito moved to adopt the minutes from the February 24, 2026 meeting.
Daniel Foreman — Addressed as Mr. Chairman in the follow-up question.
Daniel Foreman — Addressed as Chairman Foreman.
Daniel Foreman — Addressed as Chairman Foreman and as the chair asking a question.
Daniel Foreman — Asked whether mandated labeling of this information would be considered consumer protection.
Daniel Foreman — Chair recognized the next question and procedural flow.
Daniel Foreman — Chair addressed the witness and facilitated the exchange.
Daniel Foreman — Chair thanked the witness and recognized the next senator.
Daniel Foreman — Chair is addressed by the witness during the response.
Daniel Foreman — Chair redirected the question and closed the witness’s questioning.
Daniel Foreman — Chair offered the opportunity for Senator Taves to respond later during closing.
Daniel Foreman — Chair welcomed the witness and reassured him.
Daniel Foreman — Daniel Foreman, as chair, initiated a roll call vote on the substitute motion to hold Senate Bill 1310 in committee. He then recorded his nay vote and announced the tally of five affirmative and four negative votes. The motion carried, Senate Bill 1310 was held in committee, and the chair thanked attendees and witnesses before adjourning the committee.
Ali Jarnigan — Senator Taves said she worked with him on the legislation and would explain details.
Allison Jarnigan — Introduced herself, said she represents herself, and explained her involvement in bringing the bill forward.
Allison Jarnigan — Identified as Kyle Jarnigan's wife.
Brian Lenney — Senator Lenney raised concerns about the bill’s application to aborted fetal cells and questioned how anyone could determine the source of such cells. He briefly followed up, then indicated he had no further questions. Later speakers referenced his earlier point about the difficulty of identifying fetal tissue sources and noted similar confusion.
Brian Lenney — Brian Lenney questioned how the bill would be enforced if enacted, asking who should answer his questions, what the practical enforcement mechanism would look like, and whether responsibility would fall on retailers, producers, or both. He also referenced the bill’s delineations and examples from the chart while continuing to probe how officials would determine what applies to whom.
Brian Lenney — He argued the bill raised federal preemption concerns and said he would support holding it in committee.
Brian Lenney — He said the bill would likely be preempted by federal law, called it a federal issue, and supported holding it in committee.
Brian Lenney — Said he agreed with the concept but thought it was not a state issue and would reluctantly vote to hold the bill in committee.
Brian Lenney — Cited by Senator Guthrie as having drawn out the FDA labeling conflict well.
Brian Lenney — Referenced as having explained the FDA labeling conflict well.
Brian Lenney — Referenced as having explained the FDA labeling conflict well.
Brian Lenney — Referenced as having explained the FDA labeling conflict well.
Brian Lenney — Referenced in connection with the FDA labeling conflict and earlier discussion.
Brian Lenney — Voted yes on the substitute motion to hold Senate Bill 1310 in committee.
Ms. Jarnigan — Ms. Jarnigan explained her background in biology and teaching, said she had researched fetal tissue use, and discussed how fetal cell lines are treated under the law. She also clarified the bill’s labeling requirement, stating that it would not necessarily require a separate label but would require the ingredient to be identified as fetal tissue on the existing label, and noted when she was unsure she would defer the question to the sponsor.
Jim Guthrie — Questioned Jarnigan about whether her handouts indicated outside involvement beyond her private-citizen testimony.
Jim Guthrie — Jim Guthrie repeatedly questioned the bill’s regulatory burden and enforceability, asking how compliance could be verified without a physical note, whether a scientific advisory committee or similar oversight would be needed, and how the state could determine adherence to labeling and protocol requirements. He also raised concerns that the proposal could impose burdens on businesses and questioned claims of negligible fiscal impact.
Jim Guthrie — Jim Guthrie is referenced as the senator raising a question, then he asks the witness about whether someone in an emergency situation would have legal recourse if they were not fully informed about fetal cells. The exchange centers on informed consent, emergency circumstances, and the legal implications of disclosure, followed by the witness beginning to respond.
Jim Guthrie — The transcript appears to misrecognize a senator's name as 'Senator Mourning'; the context suggests a committee member speaking against advancing the bill.
Jim Guthrie — He was identified as the second on the substitute motion to hold the bill in committee.
Jim Guthrie — Supported the original motion, raised concerns about preemption, and cited a California labeling example involving his son-in-law's business.
Jim Guthrie — Was thanked by Senator Lenney and later spoke in support of the original motion.
Jim Guthrie — Continued his remarks, saying California's additional labeling requirement showed the concept could be handled in practice and that he supported the original motion.
Jim Guthrie — Said the California example showed the concept could be handled and supported the original motion.
Jim Guthrie — Said Idaho lacked the enforcement mechanism and regulatory capacity to implement the bill and would vote no.
Jim Guthrie — Said Idaho lacked the enforcement mechanism and regulatory capacity to implement the bill and would vote no.
Jim Guthrie — Supported the substitute motion to hold the bill in committee and argued the bill would create enforcement and medical-liability problems.
Jim Guthrie — Supported the substitute motion to hold the bill in committee and raised concerns about morality, enforcement, and medical liability.